(ICLR) ICON - Ratings and Ratios

Exchange: NASDAQ • Country: Ireland • Currency: USD • Type: Common Stock • ISIN: IE0005711209

Clinical Trials, Laboratory Services, Consulting, Commercialization

Stock: Life Sciences Tools & Services
Age 27.7y

MCap 14,202m
Avg Vol 768K (144M USD)

Beta 0.976
Volatility 49.10%

EPS (Earnings per Share)

EPS CAGR: -45.23%
EPS Trend: -31.4%

Last SUE: -4.00
Qual. Beats: 0

Revenue

Rev. CAGR: 2.17%
Rev. Trend: 72.9%

Last SUE: 1.53
Qual. Beats: 2

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	49.1%
Value at Risk 5%th	69.0%
Relative Tail Risk	-14.64%

Reward TTM
Sharpe Ratio	-0.07
Alpha	-22.44
CAGR/Max DD	-0.12

Character TTM
Hurst Exponent	0.488
Beta	0.976
Beta Downside	1.061

Drawdowns 3y
Max DD	63.43%
Mean DD	24.45%
Median DD	14.42%

Description: ICLR ICON January 03, 2026

ICON PLC (NASDAQ: ICLR) is a global contract research organization headquartered in Dublin that offers end-to-end outsourced services for drug and device development. Its portfolio spans strategic program design, Phase I-IV clinical trial execution, post-approval support, data analytics, decentralized and hybrid trial models, and a suite of laboratory services-including biomarker, vaccine, and GMP testing. ICON serves pharma, biotech, medical-device firms as well as government and public-health agencies across Ireland, Europe, the United States and other international markets.

Key recent metrics: FY 2023 revenue reached $4.9 billion, up ~7 % YoY, driven by strong demand for decentralized trial capabilities and real-world evidence solutions; the CRO industry is projected to grow at a CAGR of 7-8 % through 2028, underpinned by rising R&D spend (global pharma R&D outlays surpassed $210 billion in 2023) and tighter timelines for vaccine and oncology pipelines. ICON’s operating margin improved to 11.5 % as it leveraged scale efficiencies and higher-value services such as adaptive trial design and cardiac safety platforms.

For a deeper, data-driven assessment of ICON’s valuation relative to peers, you may find the analytics on ValueRay worth exploring.

Piotroski VR‑10 (Strict, 0-10) 6.5

Net Income: 599.5m TTM > 0 and > 6% of Revenue
FCF/TA: 0.06 > 0.02 and ΔFCF/TA -1.11 > 1.0
NWC/Revenue: 2.34% < 20% (prev 11.56%; Δ -9.22% < -1%)
CFO/TA 0.07 > 3% & CFO 1.18b > Net Income 599.5m
Net Debt (3.10b) to EBITDA (1.18b): 2.63 < 3
Current Ratio: 1.06 > 1.5 & < 3
Outstanding Shares: last quarter (78.1m) vs 12m ago -6.43% < -2%
Gross Margin: 26.85% > 18% (prev 0.30%; Δ 2655 % > 0.5%)
Asset Turnover: 48.06% > 50% (prev 48.26%; Δ -0.20% > 0%)
Interest Coverage Ratio: 3.96 > 6 (EBITDA TTM 1.18b / Interest Expense TTM 199.4m)

Altman Z'' (< 1.1 .. > 2.6) 1.17

A: 0.01 (Total Current Assets 3.41b - Total Current Liabilities 3.22b) / Total Assets 16.51b
B: 0.14 (Retained Earnings 2.31b / Total Assets 16.51b)
C: 0.05 (EBIT TTM 790.0m / Avg Total Assets 16.86b)
D: 0.31 (Book Value of Equity 2.23b / Total Liabilities 7.17b)
Total Rating: 1.17= BB

ValueRay F-Score (Strict, 0-100) 60.26

1. Piotroski: 6.50pt
2. FCF Yield: 5.75%
3. FCF Margin: 12.29%
4. Debt/Equity: 0.38
5. Debt/Ebitda: 2.63
6. ROIC - WACC: -2.28%
7. RoE: 6.32%
8. Revenue Trend: 72.89%
9. EPS Trend: -31.43%

What is the price of ICLR shares?

As of January 22, 2026, the stock is trading at USD 184.87 with a total of 1,186,075 shares traded.
Over the past week, the price has changed by +0.05%, over one month by +3.20%, over three months by -4.34% and over the past year by -9.85%.

Is ICLR a buy, sell or hold?

ICON has received a consensus analysts rating of 4.29. Therefore, it is recommended to buy ICLR.

Strong Buy: 11
Buy: 0
Hold: 6
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the ICLR price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	205.7	11.3%
Analysts Target Price	205.7	11.3%
ValueRay Target Price	181.9	-1.6%

ICLR Fundamental Data Overview January 21, 2026

P/E Trailing = 24.6437
P/E Forward = 13.3869
P/S = 1.7528
P/B = 1.4938
P/EG = 1.4249
Revenue TTM = 8.10b USD
EBIT TTM = 790.0m USD
EBITDA TTM = 1.18b USD
Long Term Debt = 2.88b USD (from longTermDebt, last quarter)
Short Term Debt = 567.9m USD (from shortTermDebt, last quarter)
Debt = 3.57b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.10b USD (from netDebt column, last quarter)
Enterprise Value = 17.30b USD (14.20b + Debt 3.57b - CCE 468.9m)
Interest Coverage Ratio = 3.96 (Ebit TTM 790.0m / Interest Expense TTM 199.4m)
EV/FCF = 17.38x (Enterprise Value 17.30b / FCF TTM 995.8m)
FCF Yield = 5.75% (FCF TTM 995.8m / Enterprise Value 17.30b)
FCF Margin = 12.29% (FCF TTM 995.8m / Revenue TTM 8.10b)
Net Margin = 7.40% (Net Income TTM 599.5m / Revenue TTM 8.10b)
Gross Margin = 26.85% ((Revenue TTM 8.10b - Cost of Revenue TTM 5.93b) / Revenue TTM)
Gross Margin QoQ = 22.32% (prev 27.84%)
Tobins Q-Ratio = 1.05 (Enterprise Value 17.30b / Total Assets 16.51b)
Interest Expense / Debt = 1.41% (Interest Expense 50.2m / Debt 3.57b)
Taxrate = 8.94% (77.7m / 869.2m)
NOPAT = 719.3m (EBIT 790.0m * (1 - 8.94%))
Current Ratio = 1.06 (Total Current Assets 3.41b / Total Current Liabilities 3.22b)
Debt / Equity = 0.38 (Debt 3.57b / totalStockholderEquity, last quarter 9.33b)
Debt / EBITDA = 2.63 (Net Debt 3.10b / EBITDA 1.18b)
Debt / FCF = 3.12 (Net Debt 3.10b / FCF TTM 995.8m)
Total Stockholder Equity = 9.48b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.56% (Net Income 599.5m / Total Assets 16.51b)
RoE = 6.32% (Net Income TTM 599.5m / Total Stockholder Equity 9.48b)
RoCE = 6.39% (EBIT 790.0m / Capital Employed (Equity 9.48b + L.T.Debt 2.88b))
RoIC = 5.58% (NOPAT 719.3m / Invested Capital 12.90b)
WACC = 7.86% (E(14.20b)/V(17.77b) * Re(9.51%) + D(3.57b)/V(17.77b) * Rd(1.41%) * (1-Tc(0.09)))
Discount Rate = 9.51% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -3.07%
[DCF Debug] Terminal Value 77.01% ; FCFF base≈1.09b ; Y1≈979.9m ; Y5≈840.0m
Fair Price DCF = 162.6 (EV 15.51b - Net Debt 3.10b = Equity 12.41b / Shares 76.4m; r=7.86% [WACC]; 5y FCF grow -12.41% → 2.90% )
EPS Correlation: -31.43 | EPS CAGR: -45.23% | SUE: -4.0 | # QB: 0
Revenue Correlation: 72.89 | Revenue CAGR: 2.17% | SUE: 1.53 | # QB: 2
EPS next Quarter (2026-03-31): EPS=3.20 | Chg30d=-0.037 | Revisions Net=-4 | Analysts=13
EPS next Year (2026-12-31): EPS=13.25 | Chg30d=-0.247 | Revisions Net=-8 | Growth EPS=+1.4% | Growth Revenue=+0.2%

Additional Sources for ICLR Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle